Literature DB >> 6215962

Characterization of the IgG-Fc receptor on human platelets.

S P Karas, W F Rosse, R J Kurlander.   

Abstract

To determine quantitatively the number and avidity of receptors for the Fc portion of IgG on human platelets, we have measured the binding to platelets of human monomeric monoclonal IgG, and of small covalently crosslinked polymers of IgG1 labeled with 125I. The binding of labeled IgG1 monomers to platelets is too weak to permit quantitation. The binding of dimers or larger polymers of IgG1 is much more avid (greater at 4 degrees C than 37 degrees C), is readily reversible, and is saturable. The number of receptor sites ranges from 400 to 2000 per platelet and the mean equilibrium association constant (Ka) for the binding of dimers at 4 degrees C is 2.2 x 10(7) M-1 +/- 0.9 x 10(7) M-1. The binding is specific for the Fc portion of IgG, and IgG1 and IgG3 bind to the receptors much more avidly than IgG2 or IgG4. Unlabeled IgG1 dimers are about 7--8-fold more potent in inhibiting binding than are IgG1 monomers, and larger polymers are even more potent than dimers. Thus, the Fc receptors on platelets bind human IgG1 with the same specificity and similar avidity as Fc receptors on polymorphonuclear leukocytes (PMNs), but PMNs have about 300-fold more receptors per unit of surface area than platelets.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6215962

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Mechanism of outside-in {alpha}IIb{beta}3-mediated activation of human platelets by the colonizing Bacterium, Streptococcus gordonii.

Authors:  Ciara Keane; Helen Petersen; Kieran Reynolds; Debra K Newman; Dermot Cox; Howard F Jenkinson; Peter J Newman; Steven W Kerrigan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.

Authors:  M G Grimaldi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  The capacity of various types of immunoglobulin for intravenous use to interact with Fc receptors of human monocytes and macrophages.

Authors:  T W Jungi; J Eiholzer; P G Lerch; S Barandun
Journal:  Blut       Date:  1986-10

4.  Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Authors:  R B Stricker; P T Reyes; L Corash; M A Shuman
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Specific and nonspecific mechanisms of action of immunoglobulin G in therapy of idiopathic thrombocytopenic purpura (ITP).

Authors:  T W Jungi; P Imbach; S Barandun
Journal:  Blut       Date:  1984-06

Review 6.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

7.  Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood.

Authors:  Manash S Chatterjee; William S Denney; Huiyan Jing; Scott L Diamond
Journal:  PLoS Comput Biol       Date:  2010-09-30       Impact factor: 4.475

8.  On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2.

Authors:  P W Parren; P A Warmerdam; L C Boeije; J Arts; N A Westerdaal; A Vlug; P J Capel; L A Aarden; J G van de Winkel
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  Circulating immune complexes and platelet IgG in various diseases.

Authors:  V Puram; D Giuliani; B S Morse
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes.

Authors:  S I Rosenfeld; R J Looney; J P Leddy; D C Phipps; G N Abraham; C L Anderson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.